Multivariable Analysis of Factors Significantly Associated With Infant Colonization With Antimicrobial-Resistant GNB at NICU Discharge
| Resistance Category . | Odds Ratio . | 95% Confidence Interval . | P Valuesa . |
|---|---|---|---|
| Gentamicin-resistant GNB | |||
| Gestational age (wk) | 0.95 | 0.92–0.97 | <.01 |
| Length of stay (days) | 1.00 | 0.99–1.00 | <.01 |
| Meropenem treatment (≥10 days) | 2.68 | 2.25–3.21 | <.01 |
| Third/fourth-generation cephalosporin treatment (≥10 days) | 2.50 | 1.22–5.15 | .01 |
| Penicillin and/or ampicillin treatment (≥10 days) | 0.23 | 0.11–0.52 | <.01 |
| β-Lactam/β-lactamase combination treatment (≥5 days) | 2.30 | 1.18–4.48 | .01 |
| Third/fourth-generation cephalosporin-resistant GNB | |||
| Surgical procedureb | 1.97 | 1.54–2.50 | <.01 |
| Third/fourth-generation cephalosporin treatment (≥5 days) | 2.13 | 1.72–2.66 | <.01 |
| β-Lactam/β-lactamase combination treatment (≥5 days) | 3.07 | 1.45–6.50 | <.01 |
| Metronidazole treatment (≥5 days) | 2.55 | 1.67–3.87 | <.01 |
| Cefazolin treatment (≥5 days) | 0.36 | 0.16–0.82 | .01 |
| Carbapenem-resistant GNB | |||
| Female | 1.92 | 1.12–3.30 | .02 |
| Length of stay (day) | 1.01 | 1.00–1.01 | .03 |
| Meropenem treatment (≥10 days) | 8.12 | 5.69–11.61 | <.01 |
| Resistance Category . | Odds Ratio . | 95% Confidence Interval . | P Valuesa . |
|---|---|---|---|
| Gentamicin-resistant GNB | |||
| Gestational age (wk) | 0.95 | 0.92–0.97 | <.01 |
| Length of stay (days) | 1.00 | 0.99–1.00 | <.01 |
| Meropenem treatment (≥10 days) | 2.68 | 2.25–3.21 | <.01 |
| Third/fourth-generation cephalosporin treatment (≥10 days) | 2.50 | 1.22–5.15 | .01 |
| Penicillin and/or ampicillin treatment (≥10 days) | 0.23 | 0.11–0.52 | <.01 |
| β-Lactam/β-lactamase combination treatment (≥5 days) | 2.30 | 1.18–4.48 | .01 |
| Third/fourth-generation cephalosporin-resistant GNB | |||
| Surgical procedureb | 1.97 | 1.54–2.50 | <.01 |
| Third/fourth-generation cephalosporin treatment (≥5 days) | 2.13 | 1.72–2.66 | <.01 |
| β-Lactam/β-lactamase combination treatment (≥5 days) | 3.07 | 1.45–6.50 | <.01 |
| Metronidazole treatment (≥5 days) | 2.55 | 1.67–3.87 | <.01 |
| Cefazolin treatment (≥5 days) | 0.36 | 0.16–0.82 | .01 |
| Carbapenem-resistant GNB | |||
| Female | 1.92 | 1.12–3.30 | .02 |
| Length of stay (day) | 1.01 | 1.00–1.01 | .03 |
| Meropenem treatment (≥10 days) | 8.12 | 5.69–11.61 | <.01 |
Abbreviations: GNB, gram-negative bacilli; NICU, neonatal intensive care unit.
aP values are reported from the final fixed-effect model for each outcome. Only significant variables (P < .05) in the final models are shown.
bSurgical procedures were performed at sites 1, 2, and 3.
Multivariable Analysis of Factors Significantly Associated With Infant Colonization With Antimicrobial-Resistant GNB at NICU Discharge
| Resistance Category . | Odds Ratio . | 95% Confidence Interval . | P Valuesa . |
|---|---|---|---|
| Gentamicin-resistant GNB | |||
| Gestational age (wk) | 0.95 | 0.92–0.97 | <.01 |
| Length of stay (days) | 1.00 | 0.99–1.00 | <.01 |
| Meropenem treatment (≥10 days) | 2.68 | 2.25–3.21 | <.01 |
| Third/fourth-generation cephalosporin treatment (≥10 days) | 2.50 | 1.22–5.15 | .01 |
| Penicillin and/or ampicillin treatment (≥10 days) | 0.23 | 0.11–0.52 | <.01 |
| β-Lactam/β-lactamase combination treatment (≥5 days) | 2.30 | 1.18–4.48 | .01 |
| Third/fourth-generation cephalosporin-resistant GNB | |||
| Surgical procedureb | 1.97 | 1.54–2.50 | <.01 |
| Third/fourth-generation cephalosporin treatment (≥5 days) | 2.13 | 1.72–2.66 | <.01 |
| β-Lactam/β-lactamase combination treatment (≥5 days) | 3.07 | 1.45–6.50 | <.01 |
| Metronidazole treatment (≥5 days) | 2.55 | 1.67–3.87 | <.01 |
| Cefazolin treatment (≥5 days) | 0.36 | 0.16–0.82 | .01 |
| Carbapenem-resistant GNB | |||
| Female | 1.92 | 1.12–3.30 | .02 |
| Length of stay (day) | 1.01 | 1.00–1.01 | .03 |
| Meropenem treatment (≥10 days) | 8.12 | 5.69–11.61 | <.01 |
| Resistance Category . | Odds Ratio . | 95% Confidence Interval . | P Valuesa . |
|---|---|---|---|
| Gentamicin-resistant GNB | |||
| Gestational age (wk) | 0.95 | 0.92–0.97 | <.01 |
| Length of stay (days) | 1.00 | 0.99–1.00 | <.01 |
| Meropenem treatment (≥10 days) | 2.68 | 2.25–3.21 | <.01 |
| Third/fourth-generation cephalosporin treatment (≥10 days) | 2.50 | 1.22–5.15 | .01 |
| Penicillin and/or ampicillin treatment (≥10 days) | 0.23 | 0.11–0.52 | <.01 |
| β-Lactam/β-lactamase combination treatment (≥5 days) | 2.30 | 1.18–4.48 | .01 |
| Third/fourth-generation cephalosporin-resistant GNB | |||
| Surgical procedureb | 1.97 | 1.54–2.50 | <.01 |
| Third/fourth-generation cephalosporin treatment (≥5 days) | 2.13 | 1.72–2.66 | <.01 |
| β-Lactam/β-lactamase combination treatment (≥5 days) | 3.07 | 1.45–6.50 | <.01 |
| Metronidazole treatment (≥5 days) | 2.55 | 1.67–3.87 | <.01 |
| Cefazolin treatment (≥5 days) | 0.36 | 0.16–0.82 | .01 |
| Carbapenem-resistant GNB | |||
| Female | 1.92 | 1.12–3.30 | .02 |
| Length of stay (day) | 1.01 | 1.00–1.01 | .03 |
| Meropenem treatment (≥10 days) | 8.12 | 5.69–11.61 | <.01 |
Abbreviations: GNB, gram-negative bacilli; NICU, neonatal intensive care unit.
aP values are reported from the final fixed-effect model for each outcome. Only significant variables (P < .05) in the final models are shown.
bSurgical procedures were performed at sites 1, 2, and 3.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
